China Biologic Products Inc. (NASDAQ:CBPO)’s share price fell 1.6% on Friday . The company traded as low as $110.58 and last traded at $111.05, with a volume of 81,299 shares. The stock had previously closed at $112.88.

Several equities research analysts have recently commented on the company. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a report on Thursday, April 14th. Jefferies Group reissued a “buy” rating on shares of China Biologic Products in a report on Saturday, June 4th. Finally, Credit Suisse Group AG raised China Biologic Products from a “neutral” rating to an “outperform” rating in a report on Tuesday, July 5th.

The company’s 50 day moving average is $111.34 and its 200-day moving average is $116.95. The company has a market capitalization of $2.97 billion and a P/E ratio of 33.42.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.06. The business earned $85.60 million during the quarter, compared to the consensus estimate of $74 million. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. On average, analysts forecast that China Biologic Products Inc. will post $4.29 earnings per share for the current year.

In other China Biologic Products news, CFO Ming Yang sold 13,908 shares of China Biologic Products stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $113.64, for a total value of $1,580,505.12. Following the completion of the sale, the chief financial officer now directly owns 52,282 shares in the company, valued at $5,941,326.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Ming Yin sold 19,618 shares of China Biologic Products stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $113.64, for a total value of $2,229,389.52. Following the completion of the sale, the vice president now owns 51,419 shares of the company’s stock, valued at $5,843,255.16. The disclosure for this sale can be found here.

Several large investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC purchased a new stake in China Biologic Products during the fourth quarter valued at approximately $3,040,000. Employees Retirement System of Texas purchased a new stake in China Biologic Products during the fourth quarter valued at approximately $2,846,000. WCM Investment Management CA increased its stake in China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock valued at $8,655,000 after buying an additional 11,282 shares in the last quarter. Finally, Russell Frank Co increased its stake in China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock valued at $1,993,000 after buying an additional 5,764 shares in the last quarter.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.